Israel - hebraisk - Ministry of Health

novartis israel ltd - deferasirox - טבליות ניתנות לפיזור - deferasirox 500 mg - deferasirox - deferasirox - exjade is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and pediatric patients (aged 2 years and over).exjade is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older. chelation therapy should only be initiated when there is evidence of iron overload (liver iron concentration (lic) >5 mg fe/g dry weight (dw) following mri and serum ferritin >800 nanogram/ml).

Israel - hebraisk - Ministry of Health

novartis israel ltd - deferasirox - טבליות ניתנות לפיזור - deferasirox 250 mg - deferasirox - deferasirox - exjade is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and pediatric patients (aged 2 years and over).exjade is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older. chelation therapy should only be initiated when there is evidence of iron overload (liver iron concentration (lic) >5 mg fe/g dry weight (dw) following mri and serum ferritin >800 nanogram/ml).

Israel - hebraisk - Ministry of Health

unipharm ltd, israel - clomipramine hydrochloride - טבליה - clomipramine hydrochloride 25 mg - non selective monoamine reuptake inhibitors - depression of varying origin.in children and adolescents there is not sufficient evidence of safety and efficacy of maronil in the treatment of depressive states of varying aetiology and symptomatology. the use of maronil in children and adolescents ( 0 - 17 years of age ) in this indication is therefore not recommended. obsessive compulcive syndromes.no experience is available in children younger than 5 years of age.

Israel - hebraisk - Ministry of Health

abic ltd. - omeprazole - קפסולות - omeprazole 20 mg - omeprazole - omeprazole - acute duodenal ulcer. acute gastric ulcer. helicobacter pylori-associated peptic ulcer disease in combination with antibiotics. reflux esophagitis:- treatment ; - long-term management; - maintenance treatment for the prevention of relapse in patients with severe reflux esophagitis. treatment of severe reflux oesophagitis in children from one year of age and older. - maintenance treatment for the prevention of relapse in patients with poorly responsive peptic ulcer. - zollinger-ellison syndrome. - treatment and prevention of nsaid - associated duodenal and gastric ulcers or erosions in high risk patients.

Israel - hebraisk - Ministry of Health

dexcel ltd, israel - omeprazole - קפליות - omeprazole 20 mg - omeprazole - omeprazole - acute duodenal ulcer. acute gastric ulcer. reflux esophagitis: treatment , long - term management. maintenance treatment for the prevention of relapse in patients with severe reflux esophagitis. maintenance treatment for the prevention of relapse in patients with poorly reponsive peptic ulcer. zollinger-ellison syndrome. treatment and prevention of nsaid-associated duodenal and gastric ulcers or erosions in high risk patients. treatment of severe reflux oesophagitis in children overthe age of 6 year. helicobacter pylori - associated peptic ulcer disease in combination with antibiotics.

Israel - hebraisk - Ministry of Health

dexcel ltd, israel - omeprazole - קפליות - omeprazole 40 mg - omeprazole - omeprazole - acute duodenal ulcer. acute gastric ulcer. reflux esophagitis: treatment , long - term management. maintenance treatment for the prevention of relapse in patients with severe reflux esophagitis. maintenance treatment for the prevention of relapse in patients with poorly reponsive peptic ulcer. zollinger-ellison syndrome. treatment and prevention of nsaid-associated duodenal and gastric ulcers or erosions in high risk patients. treatment of severe reflux oesophagitis in children overthe age of 6 year.helicobacter pylori - associated peptic ulcer disease in combination with antibiotics.

Israel - hebraisk - Ministry of Health

dexcel ltd, israel - omeprazole - קפליות - omeprazole 10 mg - omeprazole - omeprazole - acute duodenal ulcer. acute gastric ulcer. reflux esophagitis: treatment , long - term management. maintenance treatment for the prevention of relapse in patients with severe reflux esophagitis. maintenance treatment for the prevention of relapse in patients with poorly reponsive peptic ulcer. zollinger-ellison syndrome. treatment and prevention of nsaid-associated duodenal and gastric ulcers or erosions in high risk patients. treatment of severe reflux oesophagitis in children overthe age of 6 year. helicobacter pylori - associated peptic ulcer disease in combination with antibiotics.

Israel - hebraisk - Ministry of Health

medison pharma ltd - galsulfase - תרכיז להכנת תמיסה לאינפוזיה - galsulfase 1 mg/ml - galsulfase - galsulfase - naglazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of mpsvi (n-acetylglactosamine 4 sulfatase deficiency maroteaux-lamy syndrome).

Israel - hebraisk - Ministry of Health

sanofi israel ltd - clopidogrel as hydrogen sulfate - טבליות מצופות פילם - clopidogrel as hydrogen sulfate 75 mg - clopidogrel - clopidogrel - prevention of atherotrobmotic eventsclopidogrel is indicated in :• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapyprevention of atherotrobmotic and thromboembolic events in atrial fibrillation: in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopid

Israel - hebraisk - Ministry of Health

teva israel ltd - clopidogrel as bisulfate - טבליה - clopidogrel as bisulfate 75 mg - clopidogrel - clopidogrel - clopidogrel is indicated for the prevention of atherothrombotic events as follows : * recent mi recent stroke or established peripheral arterial disease : - patients suffering from myocardial infarction (from a few days until less than 35 days ) - ischaemic stroke ( from 7 days until less than 6 months) or established peripheral arterial disease. - for patients with a history of recent myocardial infarction (mi) recent stroke or established peripheral arterial disease - clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not) new mi (fatal or not) and other vascular death. * acute coronary syndrome: - for patients with acute coronary syndrome [non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave mi) or st segment elevation acute myocardial infarction ] in combination with asa in medically treated patients eligible for thrombolytic therapy and those who are to be managed with percutaneous coronary intervention (with or without stent) or